(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
Ukraine's new defense minister just outlined how dire its troop shortage has become- She's been a Bond girl and a mutant. Now she's grappling with Hollywood's obsession with 'eternal youth.'
- Forget 'Outer Banks.' These Gen Z-ers just want to watch 'M*A*S*H*' and 'Gilmore Girls.'
- Language Learning Applications for Voyagers
- Home Security Frameworks with Shrewd Elements
- The Fate of Rest: Patterns in Shrewd Beds
- Greenland’s melting ice and landslide-prone fjords make the oil and minerals Trump is eyeing dangerous to extract
- Beating Scholastic Difficulties: Understudy Examples of overcoming adversity
- Alleged maple syrup scam in Quebec uncovered by Canadian broadcaster
